Open-label phase IIa trial of CYT 003 QbG10 monotherapy in patients with mild to moderate seasonal allergic rhinitis due to grass pollen allergy.
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2006
At a glance
- Drugs CMP 001 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Cytos Biotechnology
- 14 Jun 2006 New trial record.